Cargando…

Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for IDH1/2 Mutation in Adult AML

SIMPLE SUMMARY: Measurable residual disease (MRD) monitoring is crucial in managing AML to predict the risk of relapse. A better understanding of which MRD technique and molecular target will have an effective clinical impact on AML is still required. Locked nucleic acid quantitative Real-Time PCR a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kao, Hsiao-Wen, Kuo, Ming-Chung, Huang, Ying-Jung, Chang, Hung, Hu, Shu-Fen, Huang, Chein-Fuang, Hung, Yu-Shin, Lin, Tung-Liang, Ou, Che-Wei, Lien, Ming-Yu, Wu, Jin-Hou, Chen, Chih-Cheng, Shih, Lee-Yung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777301/ https://www.ncbi.nlm.nih.gov/pubmed/36551690 http://dx.doi.org/10.3390/cancers14246205

Ejemplares similares

P696: DYNAMICS OF CLONAL EVOLUTION IN CHRONIC MYELOMONOCYTIC LEUKEMIA WITH PROGRESSION TO SECONDARY ACUTE MYELOID LEUKEMIA: PAIRED-SAMPLE COMPARISON
por: Kao, Hsiao-Wen, et al.
Publicado: (2023)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR(TM) In Patients With AML And Their Clinical Impact In Mexico City
por: Olarte, Irma, et al.
Publicado: (2019)

Structural analysis of traditional Chinese complex puzzle locks
por: Shi, Kan, et al.
Publicado: (2022)

The influence of locked nucleic acid residues on the thermodynamic properties of 2′-O-methyl RNA/RNA heteroduplexes
por: Kierzek, Elzbieta, et al.
Publicado: (2005)

IDH1-mutated relapsed or refractory AML: current challenges and future prospects
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2019)

IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics
por: ElNahass, Yasser H, et al.
Publicado: (2020)

Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells
por: Wilson, Elisabeth R., et al.
Publicado: (2021)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

Locked and Unlocked Nucleosides in Functional Nucleic Acids
por: Doessing, Holger, et al.
Publicado: (2011)

IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome
por: Mourad, Stéphanie, et al.
Publicado: (2019)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

PB1783: IDENTIFICATION OF RAMAN SPECTROSCOPIC SIGNATURE OF IDH MUTATIONS IN AML IN VITRO MODEL
por: Laskowska, P., et al.
Publicado: (2022)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Locked Nucleic Acid Pentamers as Universal PCR Primers for Genomic DNA Amplification
por: Sun, Zhen, et al.
Publicado: (2008)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients
por: Wang, Jing-Han, et al.
Publicado: (2015)

In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2
por: Gbyli, Rana, et al.
Publicado: (2022)

The crystal structure of an ‘All Locked’ nucleic acid duplex
por: Eichert, André, et al.
Publicado: (2010)

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
por: Madala, Hanumantha Rao, et al.
Publicado: (2018)

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
por: Heuser, Michael, et al.
Publicado: (2020)

Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells
por: Palau, Anna, et al.
Publicado: (2023)

Data-driven modeling of core gene regulatory network underlying leukemogenesis in IDH mutant AML
por: Katebi, Ataur, et al.
Publicado: (2023)

The free energy of locking a ring: Changing a deoxyribonucleoside to a locked nucleic acid
por: Xu, You, et al.
Publicado: (2017)

Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides
por: Burdick, Andrew D., et al.
Publicado: (2014)

Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers
por: Levin, Joshua D., et al.
Publicado: (2006)

IDH1-R132 changes vary according to NPM1 and other mutations status in AML
por: Falini, Brunangelo, et al.
Publicado: (2019)

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
por: Messina, Monica, et al.
Publicado: (2022)

Stability and Mismatch Discrimination of Locked Nucleic Acid–DNA Duplexes
por: Owczarzy, Richard, et al.
Publicado: (2011)

Locked nucleic acid oligomers as handles for single molecule manipulation
por: Berezney, John P., et al.
Publicado: (2014)

8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment
por: Wu, Pei-Shan, et al.
Publicado: (2023)

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.
por: Bhide, Aniket, et al.
Publicado: (2023)

Development of a Nucleic Acid Lateral Flow Immunoassay for the Detection of Human Polyomavirus BK
por: Huang, Yi-Huei, et al.
Publicado: (2020)

Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study
por: Ho, Phoenix A., et al.
Publicado: (2010)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
por: de Botton, Stéphane, et al.
Publicado: (2023)

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
por: Wang, JingHan, et al.
Publicado: (2020)

Intravascular Large B-cell lymphoma: A case series and review of literatures
por: Ong, Yuen-Chin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gtu7buidqabbbqt3ts2bi9glme